Doganer Yusuf C, Aydogan Umit, Aydogdu Aydogan, Aparci Mustafa, Akbulut Halil, Nerkiz Polat, Turker Turker, Cayci Tuncer, Barcin Cem, Saglam Kenan
Department of Family Medicine, Turkish Military Academy Primary Care Center, Ankara, Turkey.
Coron Artery Dis. 2013 Mar;24(2):119-26. doi: 10.1097/MCA.0b013e32835b6761.
Cystatin C, which is an endogenous marker for renal function, is reported to be a novel marker for coronary atherosclerosis. In this study, we aimed to evaluate its role in determining the presence and also the severity of coronary atherosclerosis in patients with coronary artery disease (CAD).
Eighty-eight patients who underwent elective coronary angiography were enrolled in the study. Patients with heart failure, renal failure, diabetes, and thyroid disease were excluded from the study. The study population was divided into three groups: individuals with normal coronary arteries, patients with critical CAD, and patients with noncritical CAD. We also analyzed the relationship of cystatin C levels with the presence and the severity of CAD and the number of vessels involved.
The mean age of the study group was 51.73±9.21 years, and the majority were men (n=71, 80.7%). Cystatin C levels were significantly lower in patients with CAD (1334.86±93.45 vs. 836.49±411.29, P<0.001). It was significantly lower in patients with critical CAD compared with those with noncritical CAD and normal individuals (656.60±346.35, 1016.38±396.54, and 1334.86±393.45, P<0.001, respectively). Serum levels of cystatin C according to the numbers of coronary vessels such as none, single-vessel, two-vessel, three-vessel, and four-vessel disease were as follows: 1334.86±393.45, 801.67±418.70, 993.90±457.34, 744.09±354.53, and 682.30±294.43, respectively.
Lower cystatin C levels may be associated with increased severity of CAD in clinically stable patients, whereas higher levels may indicate the presence of any vulnerable plaque. It may also guide the diagnostic and therapeutic options for the clinical scene on the presentation.
胱抑素C是一种肾功能的内源性标志物，据报道它是冠状动脉粥样硬化的一种新型标志物。在本研究中，我们旨在评估其在确定冠心病（CAD）患者冠状动脉粥样硬化的存在及严重程度方面的作用。
88例行择期冠状动脉造影的患者纳入本研究。心力衰竭、肾衰竭、糖尿病和甲状腺疾病患者被排除在研究之外。研究人群分为三组：冠状动脉正常者、重度CAD患者和非重度CAD患者。我们还分析了胱抑素C水平与CAD的存在、严重程度以及受累血管数量之间的关系。
研究组的平均年龄为51.73±9.21岁，大多数为男性（n = 71，80.7%）。CAD患者的胱抑素C水平显著更低（1334.86±93.45 vs. 836.49±411.29，P < 0.001）。与非重度CAD患者和正常人相比，重度CAD患者的胱抑素C水平显著更低（分别为656.60±346.35、1016.38±396.54和1334.86±393.45，P < 0.001）。根据冠状动脉血管数量（如无血管病变、单支血管病变、两支血管病变、三支血管病变和四支血管病变）的血清胱抑素C水平如下：分别为1334.86±393.45、801.67±418.70、993.90±457.34、744.09±354.53和682.30±294.43。
在临床稳定的患者中，较低的胱抑素C水平可能与CAD严重程度增加有关，而较高水平可能表明存在易损斑块。它还可能为临床情况的诊断和治疗选择提供指导。
